Screener
UroGen Pharma URGN Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable and accrued expenses | $39,945 | $27,717 |
| Employee related accrued expenses | 12,253 | 13,516 |
| Current liabilities related to finance leases | 1,411 | 1,274 |
| Current liabilities related to operating leases | 684 | 481 |
| Other current liabilities | 7,622 | 3,430 |
| Total current liabilities | 61,915 | 46,418 |
| Non-current liabilities: |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's current debt?
- UroGen Pharma (URGN) reported current debt of $1.41M in Q2 2026.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about UroGen Pharma's current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude